MedPath

Escitalopram efficacy on quality of life and prevention of depression in breast cancer patient with mastectomy

Phase 3
Conditions
Depression.
Other mental disorders due to known physiological condition
Registration Number
IRCT20180421039376N1
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
75
Inclusion Criteria

Women 18-65 y/o
Diagnosed with breast cancer stage I,II,IIIa and undergone modified radical mostectomy with or without chemothrapy and radiotherapy
Consciously agreement
Having at least literacy of writing and reading

Exclusion Criteria

Pregnancy and lactation
History of conductive heart diseases
Severe renal failure
Moderate to severe hepatic failure
History of SSRI drugs reactions and sensitivity
Suffering from depression mood disorders, bipolar disorders or psychotic disorders based on DSM V criteria
Any condition limiting life expectancy
Any Use of anti depression or anti anxiety drugs since 2 weeks before the study
Any precipitation on group or individual psychotherapy sessions since 4 weeks before the study
Suffering from any speech disorders
Suffering from uncontrolled pain on the beginning of the study
Having suicide plans or thoughts on the beginning of the study

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Depression. Timepoint: 0-4-8-12 week. Method of measurement: DASS questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath